Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02862730 · ClinicalTrials.gov registry record · NA
Four Way Crossover Closed Loop With Exercise Detection
A NA study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT02862730: Completed NA study, sponsored by Oregon Health and Science University.
NCT02862730 is a NA study that has completed, run by Oregon Health and Science University. The registered enrollment target is 25 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02862730, a NA study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
Closed-loop systems are an emerging technology that automate hormone delivery. They are quickly paving the way to revolutionize the treatment of type 1 diabetes. Several categories have emerged: dual-hormone (insulin and glucagon) closed-loop systems and closed-loop systems with insulin only, one variety of which is the low glucose suspend safety feature now available from Medtronic (MiniMed 530G with Enlite). The study described within this protocol is designed to test the efficacy of a new closed-loop algorithm for managing blood glucose in people with type 1 diabetes before and after exercise. The new algorithm will have 3 modes: a single hormone insulin only mode, a dual-hormone insulin and glucagon mode and an insulin only mode with predictive low glucose suspend, all with an exercise detection algorithm. The purpose of this study is to determine whether a dual hormone AP with an exercise detection algorithm outperforms both single hormone AP and a low glucose suspend algorithm and sensor augmented pump therapy using the subject's own insulin pump.
Primary Outcome
Assess the percent of time that the Dexcom G4 Share reported sensor glucose values less than 3.9 mmol/L using Dexcom sensor downloads across all four arms.
Interventions
- DEVICE Artificial Pancreas Controller in Dual Hormone Mode
- DEVICE Artificial Pancreas Controller in Single Hormone Mode
- DEVICE Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode
- DEVICE Subject's insulin pump
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-10 |
| Est. Completion | 2018-01-31 |
| Phase | NA |
What the finished NCT02862730 record still lists
NCT02862730 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 4 interventions - of which Artificial Pancreas Controller in Dual Hormone Mode is the first listed.
NCT02862730 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02862730 about?
NCT02862730 is a clinical study titled "Four Way Crossover Closed Loop With Exercise Detection". Closed-loop systems are an emerging technology that automate hormone delivery. They are quickly paving the way to revolutionize the treatment of type 1 diabetes. Several categories have emerged: dual-hormone (insulin and glucagon) closed-loop systems and closed-loop systems with insulin only, one va...
What is the current status of trial NCT02862730?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2016-10. Estimated completion is 2018-01-31.
What interventions are being tested in trial NCT02862730?
The interventions under investigation include: Artificial Pancreas Controller in Dual Hormone Mode (DEVICE), Artificial Pancreas Controller in Single Hormone Mode (DEVICE), Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode (DEVICE), Subject's insulin pump (DEVICE).
Who is sponsoring clinical trial NCT02862730?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02862730's enrollment target sits among peer trials
25 1712th of 2000 higher than 265 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia